Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

SUNNYVALE, Calif., Feb. 12, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and to ibrutinib monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia (WM), both of which are B-cell malignancies.

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development."[i]  The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacylics, together with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with MCL and WM. The company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

"This is a historic moment in oncology. We are truly honored to have received this Breakthrough Designation and are pleased for patients and clinicians with the FDA's decision to expedite the development of ibrutinib,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014   Easy Breathe , ... , today announced that it now offers the revolutionary ... CPAPs are the first sleep apnea therapy devices with ... and easy to track and share real-time data on ... of their CPAP therapy.  In addition, the internal modem ...
(Date:9/30/2014)... Sept. 30, 2014 Valeant Pharmaceuticals International, Inc. ... announced that the company,s Bridgewater, New Jersey ... U.S. Food and Drug Administration (FDA) relating to an ... regards to Sculptra Aesthetic injectable, which was divested to ... the management of Valeant,s contract manufacturers (rather than Valeant,s ...
(Date:9/30/2014)... 2014 BioStructures, LLC has been awarded ... Tissue Banks (AATB), it was announced today by ... Accreditation follows an intensive nine-month process, including ... inspector.  It establishes that the level of medical, ... or exceeds the standards set by the AATB.  ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Biostructures, LLC Earns AATB Accreditation 2
... Patients For Over a Decade, SAN FRANCISCO, ... benefit from arthroscopic surgery long term,according to a ... for Sports Medicine Specialty Day at The Moscone ... surgery, rather than conservative,methods, yielded excellent results., ...
... LARGO, Fla., March 7 AlphaMed Pharmaceuticals,Corporation announced ... version of the therapeutic protein alpha 1-antitrypsin (AAT).,AlphaMed ... production system in yeast. The yeast has been ... that which is,manufactured by the human body., ...
Cached Medicine Technology:Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 2Controversial Shoulder Surgery for First-time Dislocation Proven Effective Long-Term 3AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin 2
(Date:9/30/2014)... 30, 2014 A group of Americans is ... an epidemic that, left unchecked, could create a catastrophic, global ... headed to Africa. John Rogers, the Executive Director the Eugene ... to fight a disease most think mankind conquered long ago: ... years ago is on the comeback in several countries - ...
(Date:9/30/2014)... 2014 Two revolutionary procedures now being utilized ... gum disease a far less painful and far more ... you’ve ever felt electric shock waves surge through your teeth ... beverage, it’s possible you already know the impact of receding ... general dentist in West Palm Beach, and a Fellow in ...
(Date:9/30/2014)... (HealthDay News) -- Medicare should cover low-dose computed tomography ... the disease, a coalition of more than 60 patient ... the Lung Cancer Alliance, the Society of Thoracic Surgeons, ... and the American Society of Clinical Oncology, made its ... Centers for Medicare & Medicaid Services (CMS). Such ...
(Date:9/30/2014)... Defense has made progress in reducing the stigma associated ... and post-traumatic stress disorder, but more improvement is still ... Despite efforts of both the Defense Department and the ... service members still do not seek needed care for ... concerted effort to promote treatment as a way to ...
(Date:9/30/2014)... that causes a rare premature aging disease could lead ... unstoppable cell division that makes cancer so deadly. ... U-M Health System recently discovered a protein mutation that ... hematopoietic stem cells can,t regenerate and make new blood. ... cancer and bone marrow failure. , But the ...
Breaking Medicine News(10 mins):Health News:US Delegation Heads to North Korea to Combat Tuberculosis Epidemic 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2
... Nutrition Month(R), and Cabot Creamery Cooperative(R) offers, ... they age, CABOT, Vt., Feb. 19 March ... Dietetic Association,s campaign to promote,the importance of eating a ... to eat better, smarter and,healthier. Research by the US ...
... Harvard-Trained Cosmetic and Laser,Surgeon and Board Certified ... Relations to spearhead her PR campaign. Dr. Jacob,Director ... performs a variety of medical procedures and services, ... A veteran in the field, Dr. Jacob works ...
... Hyperactivity Disorder in ... Throughout Asia -, NEW HAVEN, Conn. and KORTRIJK, ... specialty pharmaceuticals company,focused on bringing proprietary medicines to the ... announced that RHEI has,licensed from MethaPharma the exclusive right ...
... Feb. 18 The following was,released today by ... Ambulance diversion? Crowded,emergency departments? Reports and articles over ... longer emergency department wait times (in,excess of 12 ... than one,third of area hospitals were to divert ...
... An international team of scientists led by a University ... into the realm of consciousness. , The scientists have ... perception, by showing how single neurons in the human ... of Leicester bioengineer Dr Rodrigo Quian Quiroga is spearheading ...
... atrial fibrillation, analysis shows , , MONDAY, Feb. 18 (HealthDay ... that are prescribed to lower cholesterol levels may also ... that boosts the odds of a stroke, French researchers ... more than 3,500 participants showed that those patients who ...
Cached Medicine News:Health News:Hey Boomers, Here's to Your Health! 2Health News:Hey Boomers, Here's to Your Health! 3Health News:Hey Boomers, Here's to Your Health! 4Health News:Hey Boomers, Here's to Your Health! 5Health News:Dr. Carolyn Jacob Hires Empower Public Relations 2Health News:RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia 2Health News:RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia 3Health News:Gilbert Hospital Turns the Tables on the Flu 2Health News:Scientists explore consciousness 2Health News:Scientists explore consciousness 3Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 2Health News:Cholesterol-Lowering Drugs May Ease Irregular Heartbeat 3
... spinal procedures. The SpineAssist platform for enhancing ... solution that enables surgery to be performed ... currently answers a growing need for accurate ... pedicle screw insertion for spine fusion procedures. ...
ACRYSOF®, Posterior Chamber Intraocular Lenses are indicated for the replacement of the human lens to achieve visual correction of aphakia in patients sixty years and older. These lenses are i...
Single piece PMMA lens, AC depth: 4.7....
Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
Medicine Products: